Latest Hotspot

TiumBio Reveals Promising Early Data for Hemophilia Candidate TU7710 at ISTH 2024

28 June 2024
3 min read

TiumBio Co., Ltd., a biopharmaceutical firm in the clinical stages of creating pioneering therapies for rare and untreatable conditions, revealed today that it shared clinical results of its hemophilia therapy, TU7710, at the 32nd Congress of the International Society on Thrombosis and Haemostasis. Additionally, the company is initiating new global collaborations.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

TiumBio is actively running a double-blind, placebo-controlled Phase 1a clinical study to evaluate the pharmacokinetics, pharmacodynamics, and safety profile of TU7710 in healthy male adults. During a recent conference, interim data from 32 participants were unveiled, covering dose ranges from 100 μg/kg to 800 μg/kg.

According to the clinical data shared at the ISTH conference, TU7710 exhibited an average half-life between 10.4 and 16.6 hours across different dosage groups. This is significantly longer—5 to 7 times—than the 2.3-hour half-life of NovoSeven, a standard hemophilia treatment used for patients with antibodies against conventional therapies. More importantly, no serious adverse or thromboembolic events were noted, and the majority of adverse events were mild in nature.

The term "half-life" describes the time required for the drug's concentration in the bloodstream to fall by half, which is crucial for the drug's efficacy duration. Given NovoSeven's brief half-life, hemophilia A or B patients with inhibitors are recommended to receive doses every two hours during bleeding episodes to achieve hemostasis, posing a challenge for both patients and healthcare providers.

TU7710 represents a recombinant factor VIIa with an extended half-life, achieved through TiumBio's transferrin fusion technology. The company aims to launch a Phase 1b clinical trial of TU7710 involving hemophilia patients in Europe by the latter half of this year.

“While NovoSeven has been a cornerstone in hemophilia treatment, generating $10 billion in sales over the last nine years, its short half-life presents notable medical challenges,” commented Hun-Taek Kim, Ph.D., MBA, CEO of TiumBio. “The prolonged half-life of TU7710, demonstrated in preclinical and initial human trials, significantly enhances the drug’s commercial potential,” he concluded..

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of June 28, 2024, there are 51 investigational drugs for the factor VIIa target, including 30 indications, 62 R&D institutions involved, with related clinical trials reaching 73, and as many as 14186 patents.

TU-7710 holds promise for addressing the unmet medical needs of patients with hemophilia A and B, as well as other related hemic and lymphatic diseases. As the drug progresses through clinical development, further data and insights will be needed to assess its potential impact on patient outcomes and its eventual market availability.

图形用户界面, 文本, 应用程序

描述已自动生成

Is Tucatinib approved by the FDA?
Drug Insights
3 min read
Is Tucatinib approved by the FDA?
28 June 2024
Tucatinib (Tukysa) is an FDA-approved medication for treating HER2-positive breast cancer, specifically in cases where the cancer is metastatic or inoperable.
Read →
Phase 3 FLOW Study: 1mg Ozempic® Reduces Kidney Disease Risk
Latest Hotspot
3 min read
Phase 3 FLOW Study: 1mg Ozempic® Reduces Kidney Disease Risk
28 June 2024
The Phase 3 FLOW study presented at the 84th ADA Scientific Sessions showed a 1 mg dose of Ozempic® (semaglutide) injection decreased the risk of kidney disease-related events.
Read →
Is Selumetinib approved by the FDA?
Drug Insights
3 min read
Is Selumetinib approved by the FDA?
28 June 2024
The U.S. Food and Drug Administration (FDA) granted approval for Selumetinib on April 10, 2020. Selumetinib is used specifically for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Read →
Innovent Reveals Phase 3 Results of Mazdutide for Weight Control at ADA 84th Sessions
Latest Hotspot
3 min read
Innovent Reveals Phase 3 Results of Mazdutide for Weight Control at ADA 84th Sessions
28 June 2024
Innovent Unveils Phase 3 Study Outcomes of Mazdutide for Weight Control at the ADA's 84th Scientific Sessions.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.